OBJECTIVE
To compare the value of Qa surveillance versus monitoring.
STUDY
• Meta-analysis was performed on the randomized controlled trials (RCTs) comparing the two screening strategies (monitoring and Qa surveillance); • To test the real-world benefits of Qa surveillance, the expected RCT-based thrombosis and access loss rates with Qa surveillance were compared with the rates with monitoring reported in observational studies.
RESULTS
• Correcting stenosis identified by Qa surveillance significantly halved the risk of thrombosis [relative risk (RR) = 0.51, 95% confidence interval (CI) 0.35-0.73] and access loss (RR = 0.47, 95% CI 0.28-0.80) in comparison with intervention prompted by clinical signs of access dysfunction.
• One small RCT designed to identify an optimal Qa threshold showed that stenosis repair at Qa >500 mL/ min produced a significant 3-fold reduction in the risk of thrombosis (RR = 0.37, 95% CI 0.12-0.97) and access loss (RR = 0.36, 95% CI 0.09-0.99) in comparison with intervening when Qa dropped to <400 mL/ min as per guidelines.
CONCLUSION
• Results suggest that, in clinical practice, adopting Qa surveillance may only be worthwhile at centres with high thrombosis and access loss rates associated with monitoring.
• The expected thrombosis and access loss rates with surveillance were only lower than with monitoring when a Qa >500 mL/min was considered (2.4, 95% CI 1.0-4.6 and 2.2, 95% CI 0.7-5.0 versus 9.4, 95% CI 7.4-11.3 and 10.3, 95% CI 7.7-13.4 events per 100 AVFs-year, P ≤ 0.024); • Qa thresholds >500 mL/min for elective stenosis repair should be adopted.
